CRIS Current Research Information System

CAMPANA, DAVIDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.435
NA - Nord America 9.129
EU - Europa 5.791
SA - Sud America 573
AF - Africa 508
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.449
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.017
VN - Vietnam 3.349
SG - Singapore 2.564
CN - Cina 2.537
GB - Regno Unito 1.528
DE - Germania 783
IT - Italia 774
HK - Hong Kong 686
SE - Svezia 619
FR - Francia 436
IN - India 429
BR - Brasile 415
RU - Federazione Russa 335
UA - Ucraina 289
KR - Corea 251
IE - Irlanda 227
FI - Finlandia 155
JP - Giappone 155
NL - Olanda 149
CH - Svizzera 137
ZA - Sudafrica 135
TG - Togo 104
CI - Costa d'Avorio 103
EE - Estonia 94
AR - Argentina 76
SC - Seychelles 67
CA - Canada 52
ID - Indonesia 50
PH - Filippine 50
BD - Bangladesh 49
JO - Giordania 48
BE - Belgio 44
NG - Nigeria 44
IQ - Iraq 42
TH - Thailandia 42
MX - Messico 39
AT - Austria 37
PL - Polonia 37
TR - Turchia 37
BG - Bulgaria 36
TW - Taiwan 30
EC - Ecuador 22
PK - Pakistan 20
IR - Iran 18
ES - Italia 16
GR - Grecia 16
MA - Marocco 16
CL - Cile 15
SA - Arabia Saudita 15
CO - Colombia 12
LT - Lituania 12
UZ - Uzbekistan 12
CZ - Repubblica Ceca 10
PE - Perù 10
EG - Egitto 9
RO - Romania 9
AU - Australia 8
HR - Croazia 8
HU - Ungheria 8
LB - Libano 8
PY - Paraguay 8
AE - Emirati Arabi Uniti 6
AL - Albania 6
MY - Malesia 6
CR - Costa Rica 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
MD - Moldavia 5
NP - Nepal 5
TN - Tunisia 5
DK - Danimarca 4
IL - Israele 4
KZ - Kazakistan 4
SN - Senegal 4
UY - Uruguay 4
VE - Venezuela 4
GY - Guiana 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
KW - Kuwait 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
CY - Cipro 2
ET - Etiopia 2
EU - Europa 2
LU - Lussemburgo 2
MK - Macedonia 2
PR - Porto Rico 2
SI - Slovenia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
GF - Guiana Francese 1
Totale 26.426
Salva come PNG Salva come JPEG
Città #
Singapore 1.732
Southend 1.341
Ashburn 995
Fairfield 859
Ho Chi Minh City 778
Hanoi 661
Hong Kong 654
Chandler 624
San Jose 583
Hefei 534
Santa Clara 397
Woodbridge 389
Seattle 388
Houston 357
Wilmington 345
Princeton 316
Cambridge 287
Beijing 286
Dong Ket 262
Seoul 228
Dublin 224
Boardman 222
Ann Arbor 203
Lauterbourg 187
Jacksonville 175
Los Angeles 160
Bologna 155
Tokyo 129
Helsinki 126
Bern 125
Da Nang 117
Westminster 114
Lomé 104
New York 104
Abidjan 103
Nanjing 102
Padova 96
Berlin 94
Milan 90
Dallas 86
Haiphong 86
Council Bluffs 76
Redondo Beach 71
Frankfurt am Main 70
Buffalo 64
Shanghai 63
Jinan 61
Guangzhou 59
Shenyang 56
São Paulo 52
Tianjin 52
Saint Petersburg 51
Bengaluru 50
Changsha 49
Nanchang 49
San Diego 49
Amman 47
Abeokuta 42
Biên Hòa 42
Hải Dương 42
Medford 41
Munich 41
Des Moines 39
Chicago 37
Can Tho 36
Redmond 36
Mülheim 35
Sofia 34
Quận Bình Thạnh 33
Turin 33
Ha Long 31
Jakarta 30
Bremen 29
Brussels 29
Florence 29
Ninh Bình 29
Hebei 27
Johannesburg 26
Wuhan 26
Yubileyny 26
Zhengzhou 26
Bắc Giang 24
Tongling 24
Hangzhou 23
Nuremberg 23
Phoenix 23
Warsaw 23
Amsterdam 22
London 22
Thái Nguyên 22
Atlanta 21
Bắc Ninh 21
Fuzhou 21
Lappeenranta 21
Falkenstein 20
Jiaxing 20
The Dalles 20
Bến Tre 19
Bangkok 18
Vienna 18
Totale 16.941
Salva come PNG Salva come JPEG
Nome #
Metastatic 5-mm rectal neuroendocrine carcinoma. 629
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 390
Radiomic analysis performed on 68Ga-DOTANOC PET/CT allows discriminating primary pancreatic neuroendocrine tumour grading 297
A [68Ga]Ga-DOTANOC PET/CT radiomic model for non-invasive prediction of tumour grade in pancreatic neuroendocrine tumours 256
MicroRNA and Metabolic Profiling of a Primary Ovarian Neuroendocrine Carcinoma Pulmonary-Type Reveals a High Degree of Similarity with Small Cell Lung Cancer 243
Comparing PET-derived semiquantitative parameters and radiomic features in discriminating G1 and G2 primary pancreatic neuroendocrine tumours in 68Ga-DOTANOC PET/CT 234
Basis for treatment of functioning neuroendocrine tumours. 227
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. 224
Chromogranin A: is it a useful marker of neuroendocrine tumors? 222
Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study 220
Adult coeliac disease diagnosed by endoscopic biopsies in the duodenal bulb. 217
Endocrine pancreatic tumors: factors correlated with survival. 216
68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma 214
A case of primary pancreatic lymphoma. 210
WHO 2010 classification of pancreatic endocrine tumors. Is the new always better than the old? 208
Is surgery the best treatment for sporadic small (≤2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience 208
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. 198
Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine tumors? 196
Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study 195
68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. 192
The ELISA fecal elastase-1 polyclonal assay reacts with different antigens than those of the monoclonal assay. 192
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review 191
18f-fdg pet/ct for restaging gastric cancer after surgical resection 190
Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: a prospective study 190
Radiomic analysis could allow detecting misassigned bioptic grading when discriminating G1 and G2 primary pancreatic neuroendocrine tumours imaged with 68Ga-DOTANOC PET/CT 190
Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. 188
Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. 184
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 184
Endocrine tumors of the ileum: factors correlated with survival. 184
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors 183
The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. 183
G1/G2 discrimination of pNET with [68Ga]Ga-DOTANOC PET/CT quantitative parameters: is it feasible? 183
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. 182
Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience 182
Pancreatic involvement in systemic sarcoidosis. A case report. 179
A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience 179
Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. 172
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 171
Medical treatment of endocrine gastroenteropancreatic tumors. 170
Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials 170
Zollinger-Ellison syndrome. Diagnosis and therapy. 168
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 166
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients 165
Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis 165
Water-related techniques in colonoscopy: the end justifies the means! 164
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 164
Siblings Diagnosed With Primary Neuroendocrine Tumor of the Left Hepatic Duct 163
Efficacy and Cost-Effectiveness of Immediate Surgery versus a Wait-and-See Strategy for Sporadic Nonfunctioning T1 Pancreatic Endocrine Neoplasms. 162
[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? 161
68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. 161
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 159
Sedation during colonoscopy and the benefits of lubrication 158
Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. 158
Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms 157
Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours 157
Lubrication during colonoscopy: a forgotten factor. 156
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 155
Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. 155
Patient-reported outcomes in patients with endocrine tumors of the Ileum 154
An Update on Appendiceal Neuroendocrine Tumors 153
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study 153
Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires. 151
Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis 151
Warm water and oil assistance in colonoscopy 150
Appendiceal goblet cell carcinoma has marginal advantages from perioperative chemotherapy: a population-based study with an entropy balancing analysis 149
Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. 149
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study 149
Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. 148
Radiomic Model Discriminating Low Grade Pancreatic Neuroendocrine Tumours Assessed by Biopsy of the Primary Lesion 147
Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs 147
Long-term survival in neuroendocrine tumors of the pancreas. 146
WHO-2010 and WHO-2000 classifications for pancreatic endocrine tumors. Is it time to change ? 145
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? 145
Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. 144
Evaluation of patient-reported outcome in subjects treated medically for acute pancreatitis: a follow-up study 143
Maffucci syndrome with hemangioma of the liver 142
Warm water and oil for the difficult colon 142
[68Ga]Ga-DOTANOC PETICT & radiomics: Potential role in discriminating tumor grade in well-differentiated primary pancreatic neuroendocrine tumors 142
Multiple gastric endocrine tumors and gastrinomas of the duodenum in a patient with a ZES MEN I 140
Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations 140
Warm water or oil-assisted colonoscopy: toward simpler examinations? 139
Sporadic Small (≤20 mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis 139
[68Ga]Ga-DOTANOC PET/CT Derived Radiomic Features Can Discriminate Pancreatic Neuroendocrine Tumours from Accessory Spleens: Preliminary Results 138
Sedation on demand and lubrication during colonoscopy: should we change our mind ? 137
Lymph Node Ratio as a Prognostic Factor in Patients with Pancreatic Endocrine Tumours JOP 137
Treatment of Zollinger-Ellison Syndrome 137
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor 136
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 136
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? 136
Quality of life in chronic pancreatitis. 134
Autoimmune pancreatitis: the classification puzzle. 134
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 133
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 133
The surgical treatment of neuroendocrine pancreatoduodenal tumors in multiple endocrine neoplasia type 1 133
Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series. 133
The 3-Dimensional-Computed Tomography Texture Is Useful to Predict Pancreatic Neuroendocrine Tumor Grading 131
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. 130
Real-world study of everolimus in advanced progressive neuroendocrine tumors. 130
Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study 129
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 129
Totale 17.451
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021841 0 0 0 0 0 0 0 0 0 104 127 610
2021/20222.869 344 83 148 174 238 131 50 216 117 132 833 403
2022/20233.048 296 400 131 351 234 245 95 181 530 97 242 246
2023/2024844 87 151 72 78 71 175 39 47 23 32 31 38
2024/20253.934 154 555 347 264 649 221 301 113 59 257 207 807
2025/202610.163 1.087 1.619 885 762 1.023 502 1.115 535 1.979 656 0 0
Totale 26.935